| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss on investment in equity securities | - | -95,794 |
| Net loss | -4,564,546 | -3,277,023 |
| Depreciation | 19,539 | 13,718 |
| Stock-based compensation | 2,756,603 | 1,620,386 |
| Other non-cash expenses | 343,242 | 317,279 |
| Loss on investment in equity securities | -150,029 | - |
| Amortization of right-of-use asset | 271,252 | 181,062 |
| Inventories | 11,460 | 11,460 |
| Prepaid expenses and other current assets | 76,067 | 73,786 |
| Due from related parties | 169,796 | 190,394 |
| Accrued expenses and other current liabilities | -10,384 | 23,248 |
| Tenant security deposit | -4,865 | 24,710 |
| Taxes payables | 6,170 | 23,521 |
| Operating lease liabilities | -276,981 | -181,062 |
| Net cash used in operating activities | -1,567,264 | -1,434,007 |
| Loan to affiliates | 2,079,352 | 808,240 |
| Prepayment from related parties | 145,637 | 142,461 |
| Transaction costs for land acquisition | 5,421 | - |
| Proceeds from issuance of warrants | - | 0 |
| Net cash used in investing activities | -1,939,136 | -665,779 |
| Proceeds from private placements | 2,777,120 | 1,868,750 |
| Proceeds from exercise of warrants | 991,366 | 411,667 |
| Proceeds from convertible notes payable | 9,010 | 9,010 |
| Repayment of convertible notes payable | 277,284 | - |
| Proceeds from common stock subscription | - | 170,000 |
| Proceeds from convertible notes payable - related party | 150,000 | - |
| Proceeds from short-term loans | - | 0 |
| Repayment of short-term loans | 90,281 | 58,875 |
| Proceeds from short-term bank loans | - | 0 |
| Due to related parties, net | -71,453 | -44,469 |
| Net cash provided by financing activities | 3,488,478 | 2,356,083 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 8,018 | -43,786 |
| Net decrease in cash and cash equivalents and restricted cash | -9,904 | 212,511 |
| Cash and cash equivalents at beginning of period | 863,815 | - |
| Cash and cash equivalents at end of period | 853,911 | - |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)